Showing results (1-10 of 414) with videos related to
Sort By:
Pageof 42
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 15, 2025
Avoiding resistance development to newer drugs: open research linesMatteo Rinaldi, Milo Gatti, Maddalena GiannellaMicroorganisms|January 25, 2025
Usefulness of a TDM-Guided Approach for Optimizing Teicoplanin Exposure in the Treatment of Secondary Bloodstream Infections Caused by Glycopeptide-Susceptible Enterococcus faeciumMilo Gatti, Matteo Rinaldi, Maddalena Giannella, et al.Antibiotics (Basel, Switzerland)|December 23, 2022
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired PneumoniaMilo Gatti, Maddalena Giannella, Matteo Rinaldi, et al.Antimicrobial Agents and Chemotherapy|October 16, 2023
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, et al.Therapeutic Drug Monitoring|May 2, 2025
Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim AnalysisMilo Gatti, Pier Giorgio Cojutti, Matteo Rinaldi, et al.Journal of Critical Care|April 14, 2023
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF)Milo Gatti, Matteo Rinaldi, Paolo Gaibani, et al.Infectious Disease Reports|February 24, 2022
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug MonitoringPier Giorgio Cojutti, Giacomo Fornaro, Milo Gatti, et al.Transplant Infectious Disease : an Official Journal of the Transplantation Society|July 29, 2023
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients?Milo Gatti, Matteo Rinaldi, Luciano Potena, et al.The Journal of Antimicrobial Chemotherapy|March 24, 2025
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, et al.Infectious Disease Clinics of North America|May 27, 2023
Antimicrobial Resistance in Organ Transplant RecipientsMaddalena Giannella, Matteo Rinaldi, Pierluigi VialePageof 42